Denmark’s medicines regulator has updated its guidance on digital and decentralised clinical trials to align with European Union standards, introducing new provisions for cross-border patient participation that could streamline multinational research across the continent.
Key takeaways
- Danish Medicines Agency aligns DCT guidance with EU common framework
- New guidance includes specific provisions for cross-border trial participation
- Update reflects growing adoption of digital technologies in clinical research
Growth in Digital Clinical Trial Adoption Across Europe
Regulatory frameworks supporting decentralised research, by implementation stage
Source: European Medicines Agency, 2026 | Georgian Medical Journal News
Harmonisation with European Standards
The Danish Medicines Agency updated guidance represents a significant step toward regulatory harmonisation across the European Union. The revised framework incorporates elements from the common EU guidance while maintaining Denmark-specific requirements for digital trial conduct.
Digital and decentralised clinical trials have gained prominence since the COVID-19 pandemic accelerated adoption of remote patient monitoring and virtual consultations. The updated guidance reflects this shift toward technology-enabled research methodologies in clinical practice.
Cross-Border Participation Framework
A key addition to the Danish guidance is a dedicated section addressing cross-border participation in clinical trials. This provision enables patients residing in one EU country to participate in trials conducted by sponsors based in another member state, potentially expanding recruitment pools for rare disease research.
The cross-border framework aligns with the European Medicines Agency’s broader initiative to facilitate multinational research collaboration while maintaining patient safety standards across jurisdictions.
Digital Technology Integration
The updated guidance addresses key aspects of digital trial design, including remote patient monitoring, electronic consent processes, and data security requirements. These provisions support the integration of wearable devices, mobile health applications, and telemedicine platforms in clinical research protocols.
Regulatory clarity on digital technologies is essential for pharmaceutical companies seeking to implement decentralised trial designs, which can reduce patient burden and improve recruitment rates, particularly for studies involving rare diseases or geographically dispersed populations as highlighted in recent research.
The updated guidance provides regulatory framework for cross-border digital clinical trial participation across EU member states
— Danish Medicines Agency (2026 Guidance Update)
What this means
Frequently asked questions
What are digital and decentralised clinical trials?
Digital clinical trials use technology platforms to conduct research activities remotely, while decentralised trials allow patients to participate from home or local healthcare facilities rather than centralised research sites. These approaches can reduce patient travel burden and improve trial accessibility.
How does cross-border participation work in EU clinical trials?
The updated Danish guidance allows patients in one EU country to participate in trials sponsored by organisations in other member states, provided appropriate regulatory approvals and data protection measures are in place. This expands potential participant pools for rare disease research.
What technologies are covered under the new guidance?
The guidance addresses remote patient monitoring devices, mobile health applications, electronic consent systems, and telemedicine platforms used in clinical research. It provides regulatory framework for data security, patient privacy, and quality assurance in digital trial environments.
The Danish update represents part of a broader European trend toward regulatory modernisation that supports innovation while maintaining rigorous safety standards. As more EU member states align their digital trial frameworks, researchers may benefit from streamlined approval processes and enhanced opportunities for multinational collaboration in clinical research.
Source: The guidance on digital and decentralised clinical trials (DCT) has been updated
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
